
updat revenue/lp estim cc
report exclud neuronexu contribut exh vs
prior cc report exclud neuronexu
consensu report exclud
ww algovita sale estim prior model virti entri
us sn market sometim pend fda approv
 model ex-u sn sale rel valuat base pt
reiter buy
virti launch delay algovita expans territori
ye track manag continu work fda regard
virti pma submiss provid supplementari data lead
biocompat ye result anoth review
window open approv expect
regard algovita compani still plan submit fda full bodi mr-
condit approv come month clinic evid front
algovita activ enrol patient initi hi-fi arm post-
patient expect enrol across site site current
activ complet enrol septemb nearer term data
show low rate lead disloc highlight virtu stretchabl
lead addit said continu invest salesforc
expect territori year-end current
increas hire clinician specialist free sale rep perform
direct sale activ drive territori penetration/expans
thesi believ nuvectra develop solid platform
extens clinic appeal dual coil lead design vs competitor
strand wire allow better steer-abl precis placement
implant process improv treatment result batteri life also
permit lead stretch therebi reduc risk migrat
decreas necessari revis procedur link robust lead design
also minim risk kink anoth sourc revis front
independ electrod control constant current allow waveform flexibl
tailor therapi better batteri conserv reduct side effect
continu believ stimul slightli
threshold sensat case yield result compar
better batteri conserv
continu pg
tr target
may also prove nvtr proprietari ultra-wid puls width waveform current
studi may provid high efficaci lower back pain mri head compat approv us
full bodi expect full bodi ce mark grant therebi importantli
increas appeal algovita virti sn devic share featur algovita
recharg therebi perhap doubl batteri life seen buy primari cell
treatment multipl symptom urinari and/or fecal incontin and/or pain and/or provid
back-up event lead failur physician patient interfac also optim
includ wireless transmiss head mri approv match mdt devic occur upon
approv full bodi mri compat import featur perhap sometim launch
although delay approv may allow indic launch due dilig suggest
extend batteri life like obviat one replac procedur rel mdt current devic
year mri compat primari reason physician would contempl switch
model around nvtr us sn sale given fact axon buy
enter market fall small long-liv year full-bodi mri compat
devic promis fulli updat offer fy may april
final like enter market without clinic data
valuat risk price target arriv appli ev/sal multipl nvtr
revenu month henc exhibit assum capit rais
respect ev/sal multipl in-lin average/median forward multipl
exhibit seen amongst peer group smid med-tech compani risk includ lower
penetr sn model failur achiev sn and/or mri approv
expect timelin excess spend build scs/sn salesforc result dilut
anticip gener speak competit landscap tighten boston scientif
buy introduc new highli flexibl paresthesia paresthesia-fre system
nr commit afford greater waveform flexibl still lead
marketplac strong clinic evid pedigre
page
note incom statement includ contribut neuronexu divest
page
strh estimatesstrhconsensusstrh vs consensu cc interfac compon engin statementstrh estimatesstrhconsensusstrh vs consensu cc adjust incl expens expens incom estimatesstrhconsensusstrh vs consensusmargin margin adjust incl nuvectra corpor
note entellu medic multipl calcul use transact valu respect
acquir buy entellu medic futur sale strh estim other consensu
page
ev/sal valuat nvtr total revenu ev/revenu enterpris valu debt equiti dilut share valu per futur dilut discount valu per share ofmarketrevenuerevenu cap system targetenterpris valu nuvectra corpor
page
except per share virtis- neural interfac compon total develop engin service- consolid gross research oper expens incom total oper oper incom interest expens incom net- expenses- net interest total- pre-tax incom tax expense- tax incom ep ebitda incl ebitda excl margin analysi margin oper expens incom oper ebitda margin incl ebitda margin excl profit expens growth analysi yr/yr algovita product engin servic revenu revenu revenu cc excl revenu report excl oper incom ebitda incl nuvectra corpor
develop commerci neurostimul product sn potenti db
compani spun integ formerli greatbatch headquart
plano texa
believ nuvectra develop solid platform extens clinic appeal
dual coil lead design vs competitor strand wire allow better steer-abl
precis placement implant process improv treatment result batteri life also
permit lead stretch therebi reduc risk migrat decreas necessari revis
procedur link robust lead design also minim risk kink anoth sourc
revis front independ electrod control constant current allow waveform
flexibl tailor therapi better batteri conserv reduct side effect continu
believ stimul slightli threshold sensat
case yield result compar better batteri conserv may also
prove nvtr proprietari ultra-wid puls width waveform current studi may
provid high efficaci lower back pain mri head compat approv us
full bodi expect full bodi ce mark grant therebi importantli
increas appeal algovita virti sn devic share featur algovita
recharg therebi perhap doubl batteri life seen buy primari
differenti treatment multipl symptom urinari and/or fecal incontin and/or pain and/
provid back-up event lead failur physician patient interfac also
optim includ wireless transmiss head mri approv match mdt devic
occur upon approv full bodi mri compat import featur perhap sometim
launch although delay approv may allow indic launch due dilig suggest
extend batteri life like obviat one replac procedur rel mdt current devic
year mri compat primari reason physician would contempl switch
model around nvtr us sn sale given fact axon
buy enter market fall small long-liv year full-bodi mri
compat devic promis fulli updat offer fy may
april final like enter market without clinic data
valuat risk
price target arriv appli ev/sal multipl nvtr revenu
month henc assum capit rais respect ev/
sale multipl in-lin average/median forward multipl seen amongst peer
group smid med-tech compani risk includ lower penetr sn
model failur achiev sn and/or mri approv expect timelin excess spend
build scs/sn salesforc result dilut anticip gener speak
competit landscap tighten buy introduc
new highli flexibl paresthesia paresthesia-fre system nr commit
afford greater waveform flexibl still lead marketplac
compani mention note
page
bruce nudel herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express specif
recommend report
suntrust robinson humphrey inc affili manag co-manag secur offer
follow compani within last month nvtr-u axnx-u
suntrust robinson humphrey inc make market follow compani nvtr-u axnx-u
follow compani client suntrust robinson humphrey inc invest bank
servic within last month nvtr-u axnx-u
suntrust robinson humphrey inc affili receiv compens invest bank
servic within last month nvtr-u axnx-u
analyst compens base upon stock price perform qualiti analysi commun skill
overal revenu profit firm includ invest bank revenu
matter polici practic firm prohibit offer favor research specif
research rate specif target price consider induc receipt busi
compens addit associ person prepar research report prohibit own
secur subject compani
rate price target histori nuvectra corpor nvtr-u
rate price target histori axon modul technolog inc axnx-u
creat bluematrix
creat bluematrix
page
rate price target histori boston scientif corpor bsx-u
rate price target histori medtron plc mdt-u
creat bluematrix
creat bluematrix
strh rate system equiti secur
dissemin research
suntrust robinson humphrey strh seek make reason effort provid research report
simultan elig client report avail publish restrict access area
websit elig client request password institut investor corpor
member press may also receiv research via third parti vendor includ thomson reuter
bloomberg factset capit iq addit distribut may done sale personnel via
email fax electron mean regular mail
access third parti vendor research websit http //suntrustlibrari bluematrix com/client/
pleas email research depart
contact strh sale repres
rate system effect oct
strh rate equiti secur
rate rel broader market gener next month unless
buy stock total return expect outperform relev benchmark
hold stock total return expect perform line relev benchmark
next month unless otherwis indic
sell stock total return expect under-perform relev benchmark
next month unless otherwis indic
rate nr strh invest rate opinion stock
page
coverag suspend cs indic strh rate and/or target price temporarili
suspend due applic regul and/or strh manag discret previous publish
rate target price reli upon
strh analyst price target stock cover unless otherwis indic price
target repres analyst expect stock trade next month unless
otherwis indic analyst believ insuffici valuat driver and/or invest
catalyst deriv posit neg invest view may elect approv strh
research manag assign target price likewis certain stock trade may
exhibit volatil wherebi assign price target would unhelp make invest decis
research manag approv analyst may refrain assign target sub-
legend rate price target histori chart
prior rate system oct
design base total return within period
buy total return low-beta secur
reduc total return neg low beta secur
neutral total return within bound
nr rate strh provid equiti research coverag
total return price appreci dividend price target within period unless
otherwis note beta defin secur averag beta less use bloomberg
suntrust robinson humphrey rate distribut
